Neuron23 Secures $96.5M Series D to Advance Precision Parkinson’s Therapy into Phase 2 Trial

South San Francisco, CA, June 24, 2025 (Business Wire) -- Neuron23 has closed a $96.5 million Series D funding round to advance its pipeline of precision therapies targeting genetically defined neurological and immunological diseases, with backing from major investors including SoftBank Vision Fund 2 and Kleiner Perkins. The company simultaneously announced the dosing of the first patient in its global Phase 2 NEULARK trial of NEU-411, a selective LRRK2 inhibitor for early-stage Parkinson’s disease.

Read full article here.